Biodexa Pharmaceuticals Completes $3M Final Match Payment To Access Remaining $17M CPRIT Grant For Phase 3 Study Of eRapa In Familial Adenomatous Polyposis, CEO Highlights Strategic Milestone
Portfolio Pulse from Benzinga Newsdesk
Biodexa Pharmaceuticals has completed a $3 million final match payment to access the remaining $17 million from a CPRIT grant. This funding will support a Phase 3 study of eRapa in treating Familial Adenomatous Polyposis, marking a strategic milestone for the company.
September 16, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biodexa Pharmaceuticals has secured $17 million in funding from a CPRIT grant for a Phase 3 study of eRapa, following a $3 million match payment. This is a strategic milestone for the company.
The completion of the $3 million match payment allows Biodexa Pharmaceuticals to access $17 million in grant funding, which is crucial for advancing their Phase 3 study of eRapa. This development is a significant strategic milestone, likely to positively impact BDRX's stock price in the short term as it demonstrates progress in their research and development efforts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100